D. Valeyre (Paris, France), A. Morais (Maia, Portugal), P. Rottoli (Siena, Italy)
Late-breaking abstract: Pathological analysis of acute exacerbation of idiopathic pulmonary fibrosis (IPF)
Y. Fukuda, M. Terasaki, M. Takahashi, S. Kunugi, Y. Terasaki, H. Urushiyama, A. Azuma (Bunkyo-ku, Japan)
|  |
Interstitial lung disease associated by gemcitabine chemotherapy in non-small lung cancer patients: Analysis based on the data in practical use with confirmed denominator
Y. Miura, Y. Saito, Y. Minegishi, A. Azuma, A. Gemma (Tokyo, Japan)
| |
Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity
B. T. Larsen, L. T. Vaszar, H. D. Tazelaar, T. V. Colby (Tucson, Scottsdale, United States Of America)
|  |
Could interferon-gamma 1b have a role in treatment of fibrosing NSIP?
B. Bellofiore, M. Bocchino, G. Antinolfi, A. Ponticiello, R. Di Grazia, A. Sanduzzi Zamparelli, S. Nikfam (Napoli, Italy)
| |
The clinical dynamic changes and prognosis analysis in patients with cryptogenic organizing pneumonia
X. Zhang (Beijing, China)
| |
Follow up 1 year of amiodarone pulmonary effects
G. Orlova, J. Nikolaeva, L. Kiruchina, A. Speranskaya, V. Perley, A. Gichkin (Saint-Petersburg, Russian Federation)
| |
Combined pulmonary fibrosis and emphysema. Descriptive analysis from a specialized clinic of interstitial lung disease
M. A. Nieto, B. Morales, C. Feranadez-Golfín, P. Benedetti, G. Rodriguez-Trigo, I. Gerasimova, J. L. Álvarez-Sala Walther (Madrid, Spain)
| |
The King‘s sarcoid questionnaire (KSQ): The development of a novel health related quality of life (HRQOL) questionnaire
A. Patel, R. Siegert, A. Sowemimo, D. Creamer, G. Larkin, A. Wells, I. Higginson, S. Birring (London, United Kingdom)
| |
Evaluation of the COPD assessment test (CAT) for measuring health-related quality of life in patients with interstitial lung disease
K. Nagata, K. Tomii, M. Hayashi, K. Otsuka, R. Tachikawa, K. Otsuka (Kobe, Japan)
| |
Fungal colonization in interstitial lung diseases
I. Sivokozov, O. Lovacheva, E. Shmelev, E. Larionova (Moscow, Russian Federation)
| |
Forced vital capacity decreases rapidly in patients with idiopathic upper lobe-dominant pulmonary fibrosis
K. Watanabe, T. Harada, T. Hirota, K. Nabeshima, M. Fujita, N. Nagata (Fukuoka, Japan)
| |
Pulmonary hypertension and right ventricular impairment in patients with interstitial pneumonia
N. Karoli, A. Rebrov (Saratov, Russian Federation)
| |
Interstitial lung diseases in Europe
R. Carbone, R. Filiberti, E. Savarino, R. Ghio, A. Ballestrero (Gneoa, Genoa, Italy)
| |
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension
G. S. Zimmermann, K. Jakob, W. von Wulffen, P. Huppmann, T. Meis, V. Arias Herrera, C. Baezner, F. Ihle, J. Geiseler, J. Fresenius, H. H. Leuchte, R. Baumgartner, J. Behr, C. Neurohr (Munich, Gauting, Bochum, Germany)
| |
Pulmonary hypertension in patients with interstitial lung disease
Z. Dogrul, S. Erginel, H. Yildirim, G. Ak, R. Ozkan, F. Alatas, M. Metintas (Eskisehir, Turkey)
| |
Resting PaO2 and 6MWT as diagnostic index for nocturnal oxygen desaturation in diffuse parenchymal lung diseases
S. Singh, M. L. Gupta, R. Singh, V. Singh (Jaipur, India)
| |
Drug induced lung disease: 11 cases
E. Kupeli, T. Sahin Ozdemirel, Z. Erayman Ozen, G. Ulubay, S. Akcay, F. O. Eyuboglu (Ankara, Turkey)
| |
Quadriceps function is reduced in fibrotic idiopathic interstitial pneumonia
L. Mendoza, A. Gogali, S. Kemp, D. Shrikrishna, A. Jackson, G. Cavada, M. Polkey, A. Wells, N. Hopkinson (Santiago, Chile; Ioannina, Greece; London, United Kingdom)
| |
Assessment of cardiac involvement in patients with sarcoidosis
V. Kouranos, A. Rapti, E. Gialafos, K. Aggeli, M. Ntouskou, A. Kallianos, O. Anagnostopoulou, G. Tzelepis (Athens, Greece)
| |
Prognostic significance of serum markers in acute exacerbation of idiopathic interstitial pneumonias
T. Arai, Y. Inoue, K. Tachibana, Y. Inoue, A. Nishiyama, C. Sugimoto, T. Kagawa, T. Okuma, M. Akira, M. Kitaichi, S. Hayashi (Sakai, Japan)
| |